Company news

WALL STREET JOURNAL

"Nirmidas Biotech Inc., a spin-out from Stanford University with technology that amplifies fluorescence in laboratory samples in a bid to better identify disease, has raised $2 million in seed funding to begin commercialization, the company said. The funding was led by an undisclosed Washington-based firm, joined by an undisclosed angel investor and the Stanford-StartX Fund, the company said." Nirmidas Biotech Raises $2M For Gold Nanomaterial Developed at Stanford